{
  "report_rows": [
    {
      "kpi": "Net sales",
      "prediction": "BEAT",
      "answer": "pred ~$12.15B vs. cons $11.95B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Operating EBITDA",
      "prediction": "BEAT",
      "answer": "pred ~$2.32B vs. cons $2.20B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Operating EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.39 vs. cons $1.26",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "3Q26 operating EBITDA outlook",
      "prediction": "BETTER",
      "answer": "guide ~$2.15B vs. cons $1.90B (3Q26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "2026 self-help EBITDA contribution",
      "prediction": "UNCHANGED",
      "answer": "guide ~$1.10B vs. cons $1.10B (FY26)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 4.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 6.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A Q2 EBITDA/EPS beat plus a 3Q EBITDA outlook of ~$2.15B versus ~$1.90B consensus should drive upward 2026 and 2027 earnings revisions; the key incremental support is that a ~$2.15B 3Q guide would be only modestly below the ~$2.32B Q2 result despite normal seasonality, countering the market's ~$1.90B normalization assumption.",
  "day5_confidence": "MEDIUM"
}